Edwards Lifesciences Co. (NYSE:EW) Position Lessened by Greenleaf Trust

Greenleaf Trust trimmed its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,401 shares of the medical research company’s stock after selling 1,030 shares during the period. Greenleaf Trust’s holdings in Edwards Lifesciences were worth $2,699,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Edwards Lifesciences by 0.6% during the third quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company’s stock worth $3,577,163,000 after acquiring an additional 325,808 shares in the last quarter. Alliancebernstein L.P. increased its position in Edwards Lifesciences by 0.3% during the second quarter. Alliancebernstein L.P. now owns 20,512,235 shares of the medical research company’s stock worth $1,934,919,000 after buying an additional 66,763 shares during the last quarter. Wellington Management Group LLP increased its position in Edwards Lifesciences by 9.2% during the third quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock worth $1,138,575,000 after buying an additional 1,390,427 shares during the last quarter. Moneta Group Investment Advisors LLC increased its position in Edwards Lifesciences by 104,971.3% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock worth $1,148,938,000 after buying an additional 15,384,593 shares during the last quarter. Finally, Brown Advisory Inc. increased its position in Edwards Lifesciences by 5.7% during the third quarter. Brown Advisory Inc. now owns 15,133,146 shares of the medical research company’s stock worth $1,048,424,000 after buying an additional 818,849 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Down 0.6 %

Shares of EW opened at $85.94 on Friday. The stock has a market cap of $51.73 billion, a price-to-earnings ratio of 37.37, a P/E/G ratio of 4.29 and a beta of 1.05. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The company has a 50-day moving average price of $90.15 and a two-hundred day moving average price of $78.31.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, hitting analysts’ consensus estimates of $0.64. The firm had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.64 earnings per share. Equities analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Insider Activity

In other news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $94.89, for a total value of $688,426.95. Following the completion of the transaction, the chief financial officer now owns 19,074 shares in the company, valued at $1,809,931.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Robert W.A. Sellers sold 12,210 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $87.00, for a total value of $1,062,270.00. Following the completion of the sale, the senior vice president now owns 13,087 shares of the company’s stock, valued at $1,138,569. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $94.89, for a total transaction of $688,426.95. Following the completion of the sale, the chief financial officer now directly owns 19,074 shares of the company’s stock, valued at approximately $1,809,931.86. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 194,004 shares of company stock worth $17,166,254. Insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on EW. Truist Financial increased their target price on shares of Edwards Lifesciences from $78.00 to $84.00 and gave the stock a “buy” rating in a research report on Friday, December 22nd. Wells Fargo & Company raised Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price target on the stock in a research report on Friday, February 2nd. Mizuho raised their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Finally, Citigroup raised their price target on Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.73.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.